A study in melanoma patients showed that relatlimab (anti-LAG-3 mAb) plus nivolumab (anti-PD-1 mAb) led to a higher occurrence of adverse events (81.1% vs. 69.9%) and grade 3–4 irAEs (18.9% vs. 9.7%) compared to nivolumab (anti-PD-1 mAb) alone, with a notable rise in hepatitis cases (3.9% vs. 1.1%) (117). This evidence concerns the gene PDCD1 and melanoma.